Pipeline

Platform Flexibility

With LION™’s unique ability to deliver genetic material and other molecules to cells for various disease states, HDT Bio is well-positioned to address additional indications expanding the possibilities for personalized medicine and disease prevention.

Continuous Innovation

Through constant innovation and by demonstrating the versatility and flexibility of the LION™ platform in various disease indications, HDT Bio is capitalizing on the immense market potential and establishing itself as a dynamic company dedicated to transforming healthcare.

Oncology

Because HDT Bio’s technology platform enables localized, T cell-mediated immunological memory responses, LION™ has the potential to treat or prevent cancer. We are currently developing disease specific antigens associated with breast, brain, prostate, pancreatic, and other cancers.

Product (indication)
Discovery
Lead ID
IND-enabling
Phase 1
Phase 2
Phase 3
HDT-501 (breast cancer)
 
HDT-211 (glioblastoma)
 
HDT-521 (prostate cancer)
 
HDT-511 (pancreatic cancer)
 

Infectious Diseases

HDT Bio’s COVID-19 vaccine has an exceptional safety profile and has been administered to over 6,000 patients. More recently, we have been developing vaccines to target numerous life-threatening infectious diseases, including Crimean-Congo hemorrhagic fever virus (CCHF), Nipah virus, HIV, and tuberculosis.

Product (indication)
Discovery
Lead ID
IND-enabling
Phase 1
Phase 2
Phase 3
HDT-301: COVID-19
 
HDT-321: CCHF
 
HDT-331: Nipah
 
HDT-201: Respiratory ID